Prevalence of multidrug-resistant Staphylococcus aureus in diabetics clinical samples

被引:9
作者
Raju, S. [1 ,2 ]
Oli, Ajay Kumar [2 ]
Patil, S. A. [3 ]
Chandrakanth, R. Kelmani [2 ]
机构
[1] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India
[2] Gulbarga Univ, Dept Biotechnol, Gulbarga 585106, Karnataka, India
[3] Natl Inst Mental Hlth & Neurosci, Dept Neuromicrobiol, Bangalore 560029, Karnataka, India
关键词
Methicillin resistant Staphylococcus aureus; Aminoglycoside modifying enzymes; mecA and femA; AMINOGLYCOSIDE-RESISTANCE; SUSCEPTIBILITY; VANCOMYCIN; EPIDEMIOLOGY; GENTAMICIN; INFECTION; RISK; MECA;
D O I
10.1007/s11274-009-0157-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Antibiotic resistance in 40 Staphylococcus aureus clinical isolates from 110 diabetic patients (36%) was evaluated. Of these, 32 (80%) of the isolates showed multidrug-resistance to more than eight antibiotics and 35% isolates were found to be methicillin resistant S. aureus (MRSA). All 40 S. aureus strains (100%) screened from diabetic clinical specimens were resistant to penicillin, 63% to ampicillin, 55% to streptomycin, 50% to tetracycline and 50% to gentamicin. Where as low resistance rate was observed to ciprofloxacin (20%) and rifampicin (8%). In contrast, all (100%) S. aureus strains recorded susceptibility to teicoplanin, which was followed by vancomycin (95%). Genotypical examination revealed that 80% of the aminoglycoside resistant S. aureus (ARSA) have aminoglycoside modifying enzyme (AME) coding genes; however, 20% of ARSA which showed non-AME mediated (adaptive) aminoglycoside resistance lacked these genes in their genome. In contrast all MRSA isolates possessed mecA, femA genetic determinants in their genome.
引用
收藏
页码:171 / 176
页数:6
相关论文
共 24 条
[1]  
Anupurba S, 2003, Indian J Med Microbiol, V21, P49
[2]   Genotyping of methicillin-resistant Staphylococcus aureus strains from two hospitals in Bangalore, South India [J].
Arakere, G ;
Nadig, S ;
Swedberg, G ;
Macaden, R ;
Amarnath, SK ;
Raghunath, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (07) :3198-3202
[3]   Aminoglycoside-resistance mechanisms in multidrug-resistant Staphylococcus aureus clinical isolates [J].
Chandrakanth, R. Kelmani ;
Raju, S. ;
Patil, S. A. .
CURRENT MICROBIOLOGY, 2008, 56 (06) :558-562
[4]  
Clinical and Laboratory Standards Institute, 2009, M100S19 CLSI
[5]   Vancomycin acts synergistically with gentamicin against penicillin-resistant Pneumococci by increasing the intracellular penetration of gentamicin [J].
Cottagnoud, P ;
Cottagnoud, M ;
Täuber, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :144-147
[6]   Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus [J].
Cui, L ;
Ma, XX ;
Sato, K ;
Okuma, K ;
Tenover, FC ;
Mamizuka, EM ;
Gemmell, CG ;
Kim, MN ;
Ploy, MC ;
El Solh, N ;
Ferraz, V ;
Hiramatsu, K .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (01) :5-14
[7]  
Dang CN, 2002, DIABETOLOGIA, V45, pA4
[8]   Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases [J].
Goldstein, EJC ;
Citron, DM ;
Nesbit, CA .
DIABETES CARE, 1996, 19 (06) :638-641
[9]   Survival of Staphylococcus aureus inside neutrophils contributes to infection [J].
Gresham, HD ;
Lowrance, JH ;
Caver, TE ;
Wilson, BS ;
Cheung, AL ;
Lindberg, FP .
JOURNAL OF IMMUNOLOGY, 2000, 164 (07) :3713-3722
[10]   Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact [J].
Hartemann-Heurtier, A ;
Robert, J ;
Jacqueminet, S ;
Van, GH ;
Golmard, JL ;
Jarlier, V ;
Grimaldi, A .
DIABETIC MEDICINE, 2004, 21 (07) :710-715